Novosiadly, Ruslan D.
1Lilly Research Laboratories, Eli Lilly and Company, New York, New York.
4 papers on CoChat
Most cited papers
- Verified
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports
Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies
Cited by 469
- Verified
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer
TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers
Cited by 356
- Verified
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 132
- Verified
Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance
Bagchi, A., Haidar, J. N., Eastman, S. W., Vieth, M., Topper, M., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2018) · Molecular Cancer Therapeutics
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 60
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free